Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.

Both Bcl-xL and Bcl-2, antiapoptotic members of the Bcl family, are found in prostate cancer cell lines. Although these proteins may have similar antiapoptotic functions, it is not clear to what extent each serves as an antiapoptotic effector in prostate cancer cells. We engineered LNCaP and PC-3 cells to overexpress Bcl-xL protein and demonstrated that this desensitized them to the effects of cytotoxic chemotherapy. We then used two "antisense" strategies to down-regulate Bcl-xL protein expression in the parental lines. The first strategy used CS-propynylated phosphorothioate-phosphodiester oligonucleotides and co-down-regulated both Bcl-xL and Bcl-2; the second strategy used isosequential "gap-mer" phosphorothioate oligonucleotides containing 2'-O-methyl oligoribonucleotides at the 3' and 5' termini. In this case, only Bcl-xL protein expression was affected. The most active oligonucleotides of both types decreased the level of Bcl-xL protein expression to 5-30% of the control level. Multiple controls were inactive. Experiments combining oligonucleotide treatment with cytotoxic chemotherapeutic agents (paclitaxel, docetaxel, etoposide, vinblastine, carboplatin, and mitoxantrone) demonstrated a marked increase in the sensitivity of these prostate cancer cells. However, the increase in chemosensitivity in PC-3 cells was statistically identical (except mitoxantrone) for both "antisense" strategies, indicating that basal expression of Bcl-2, in contrast to that of Bcl-xL, may play little cytoprotective role in these cells.

[1]  C. Stein.  Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. , 1996, Chemistry & biology.

[2]  T. Tsuruo,et al.  Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases , 1998, Oncogene.

[3]  B. Froehler,et al.  Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. , 1995, Biochemistry.

[4]  B. Monia,et al.  Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli , 1999, Oncogene.

[5]  John Calvin Reed,et al.  Bcl-2 family proteins and mitochondria. , 1998, Biochimica et biophysica acta.

[6]  G. Kroemer,et al.  Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. , 1997, Cancer research.

[7]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[8]  V. Dixit,et al.  Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. , 1995, Oncogene.

[9]  K. Bhalla,et al.  Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. , 1997, Cancer research.

[10]  A. Macleod,et al.  Identification and Partial Purification of Human Double Strand RNase Activity , 1998, The Journal of Biological Chemistry.

[11]  A. Strasser,et al.  Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death , 1997, Oncogene.

[12]  T. McDonnell,et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. , 1997, The Journal of urology.

[13]  F. Natt,et al.  A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bcl-X expression. , 1994, Cancer research.

[15]  C. Stein,et al.  Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. , 1998, Nucleic acids research.

[16]  G. Núñez,et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. , 1997, Blood.

[17]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[18]  C. F. Bennett,et al.  The Role of Antiapoptotic Bcl-2 Family Members in Endothelial Apoptosis Elucidated with Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[19]  S. Liebhaber,et al.  Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80 S ribosome. , 1986, The Journal of biological chemistry.

[20]  G. Linette,et al.  Bcl-XL and Bcl-2 repress a common pathway of cell death , 1995, The Journal of experimental medicine.

[21]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  John Calvin Reed,et al.  Apoptosis and Bcl-2 expression in cultured murine splenic T cells. , 1995, Immunology.

[23]  E. Southern,et al.  Determining the influence of structure on hybridization using oligonucleotide arrays , 1999, Nature Biotechnology.

[24]  H. Simon,et al.  Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. , 1998, Blood.

[25]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[26]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[27]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[28]  E. Schmitt,et al.  Bax-α promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells , 1998, Cell Death and Differentiation.

[29]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Uhlmann,et al.  Minimally modified oligonucleotides - combination of end-capping and pyrimidine-protection. , 1996, Biological chemistry Hoppe-Seyler.

[31]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[32]  K. Bhalla,et al.  Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. , 1996, Cancer research.

[33]  R. Armstrong,et al.  Cell-specific Induction of Apoptosis by Microinjection of Cytochrome c , 1997, The Journal of Biological Chemistry.

[34]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[35]  S. Fesik,et al.  Bcl‐xL regulates apoptosis by heterodimerization‐dependent and ‐independent mechanisms , 1999, The EMBO journal.

[36]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[37]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[38]  P. Dent,et al.  Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL , 1999, Leukemia.

[39]  S. Liebhaber,et al.  Translationally associated helix-destabilizing activity in rabbit reticulocyte lysate. , 1984, The Journal of biological chemistry.

[40]  C. Stein,et al.  Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  N. Kyprianou,et al.  bcl‐2 over‐expression delays radiation‐induced apoptosis without affecting the clonogenic survival of human prostate cancer cells , 1997, International journal of cancer.

[42]  W. P. McLaughlin,et al.  Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis. , 1998, Radiation research.

[43]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[45]  B. Froehler,et al.  Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. , 1993, Science.

[46]  S. Freier,et al.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. , 1991, The Journal of biological chemistry.

[47]  M. Campbell,et al.  Corrigendum: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells (Cancer Letters (1995) 93 (147-155)) , 1996 .

[48]  C. Stein.  Is irrelevant cleavage the price of antisense efficacy? , 2000, Pharmacology & therapeutics.

[49]  G. Dbaibo,et al.  Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis. , 1998, The Biochemical journal.

[50]  M. Campbell,et al.  Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. , 1995, Cancer letters.

[51]  R. Rando,et al.  Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides (*) , 1995, The Journal of Biological Chemistry.